Tateda K, Standiford TJ, Pechere JC, Yamaguchi K (2004) Regulatory effects of macrolides
on bacterial virulence: Potential role as quorum-sensing inhibitors. Curr Pharm Des 10:
3055–3065
Threlfall EJ, Day M, de Pinna E, Charlett A, Goodyear KL (2006) Assessment of factors
contributing to changes in the incidence of antimicrobial drug resistance in Salmonella enterica
serotypes Enteritidis and Typhimurium from humans in England and Wales in 2000, 2002 and
- Int J Antimicrob Agents 28:389–395
Tollefson L (2004) Factual errors in review article. J Antimicrob Chemother 54:271
Toutain PL (2002) Pharmacokinetic/Pharmacodynamic integration in drug development and
dosage-regimen optimization for veterinary medicine. AAPS Pharm Sci 4(4):160–188
Turnidge J (2004) Antibiotic use in animals—prejudices, perceptions, and realities. J Antimicrob
Chemother 53:26–27
Turnidge J, Paterson DL (2007) Setting and revising antibacterial susceptibility breakpoints. Clin
Microbiol Rev 20:391–408
van den Broek PJ (1989) Antimicrobial drugs, microorganisms, and phagocytes. Rev Infect Dis
11:213–245
Wallmann J, Schro ̈ter K, Wieler LH, Kroker R (2003) National antibiotic resistance monitoring in
veterinary pathogens from sick food-producing animals: The German programme and results
from the 2001 pilot study. Int J Antimicrob Agents 22:420–428
Wassenaar TM (2005) Use of antimicrobial agents in veterinary medicine and implications for
human health. Crit Rev Microbiol 31:155–169
Wassenaar TM, Silley P (2008) Antimicrobial resistance in zoonotic bacteria: Lessons learned
from host-specific pathogens. Anim Health Res Rev 9:177–186
Wassenaar TM, Kist M, de Jong A (2007) Re-analysis of the risks attributed to ciprofloxacin-
resistantCampylobacter jejuniinfections. Int J Antimicrob Agents 30:195–201
Well M, Naber KG, Kinzig-Schippers M, So ̋rgel F (1998) Urinary bactericidal activity and
pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers
after a single oral dose. Int J Antimicrob Agents 10:31–38
WHO (2001) Surveillance standards for antimicrobial resistance, WHO, Who/CDS/CDSR/DRS/
2001.5, seehttp://www.who.int/emc
Winstanley C, Fothergill JL (2009) The role of quorum sensing in chronic cystic fibrosis Pseudo-
monas aeruginosa infections. FEMS Microbiol Lett 290:1–9
Wright DH, Brown GH, Peterson ML, Rotschafer JC (2000) Application of fluoroquinolone
pharmacodynamics. J Antimicrob Chemother 46:669–683
Yang Q, Nakkula RJ, Walters JD (2002) Accumulation of ciprofloxacin and minocycline by
cultured human gingival fibroblasts. J Dent Res 81:836–840
Zelenitsky S, Ariano R, Harding G, Forrest A (2005) Evaluating ciprofloxacin dosing for Pseudo-
monas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Anti-
microb Agents Chemother 49:4009–4014
Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ (1991) Influence of human urine on the
in vitro activity and postantibiotic effect of ciprofloxacin againstEscherichia coli.Chemotherapy
37:218–223
Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy
derived from fluoroquinolone studies. Clin Infect Dis 33(Suppl 3):S147–S156
Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother
62:434–436
264 M. Martinez and P. Silley